Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease

Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease

Background Heart failure with reduced ejection fraction (HFrEF) is a chronic disease with substantial mortality. Management of HFrEF has seen significant breakthrough after the launch of neprilysin inhibitor. The PARADIGM‐HF (Prospective Comparison of ARNI with ACEI to Determine Impacton Global Mort...

Full description

Bibliographic Details
Main Authors: Chih‐Yuan Niu, Shang‐Feng Yang, Shuo‐Ming Ou, Cheng‐Hsueh Wu, Po‐Hsun Huang, Chung‐Lieh Hung, Chih‐Ching Lin, Szu‐Yuan Li
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
ARNI
end‐stage kidney disease (ESKD)
heart failure with reduced ejection fraction (HFrEF)
sacubitril/valsartan
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.122.026407

Similar Items

Similar Items